SCHEMBL4332420

SCHEMBL4332420

COC(=O)c1nc2c(N)[nH]nc2c(F)c1Nc1ccccc1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
CLK1 P49759 1/20 0.38
KDM4E B2RXH2 6/20 0.37
CSF1R P07333 1/20 0.37
STAT3 P40763 1/20 0.36
HIF1A Q16665 1/20 0.36
MAPT P10636 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
NFKB1 P19838 1/20 0.36
HTT P42858 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
ALDH1A1 P00352 4/20 0.35
CDK5 Q00535 1/20 0.35
CDK5R1 Q15078 1/20 0.35
GAA P10253 1/20 0.35
GFER P55789 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4321847 0.88 LRRK2 (0.39) NPC1RAB9AMEN1KMT2ACLK1
SCHEMBL4340927 0.80 AURKA (0.38) NPC1RAB9AMEN1KMT2ACLK1
SCHEMBL1341312 0.78 BRD4 (0.41) NPC1RAB9AKDM4ECSF1RMAPT
SCHEMBL4330481 0.77 RAB9A (0.39) NPC1RAB9AMEN1KMT2ACLK1
SCHEMBL4340818 0.76 RAB9A (0.39) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL4322051 0.76 KDM4E (0.42) NPC1RAB9AMEN1KMT2ACLK1
SCHEMBL4329913 0.75 KDM4E (0.43) NPC1RAB9AKDM4ECSF1RMAPT
SCHEMBL4330258 0.74 BRD4 (0.40) NPC1RAB9AKDM4ECSF1RHIF1A
SCHEMBL1343394 0.73 KDM4E (0.40) NPC1RAB9AMEN1KMT2ACLK1
SCHEMBL1342341 0.72 CSF1R (0.42) NPC1RAB9AKDM4ECSF1RMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576072-B2 Heterocyclic inhibitors of MEK and methods of use thereof ARRAY BIOPHARMA INC. (US) 2009-08-18 US disclosed
US-20050153942-A1 Heterocyclic inhibitors of MEK and methods of use thereof ARRAY BIOPHARMA INC. 2005-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050153942-A1 Heterocyclic inhibitors of MEK and methods of use thereof NRAS, BRAF, MAPK9 NPC1 3658/4885RAB9A 140/4885MEN1 1841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.